Through comprehensive genomic and immune analyses, mechanisms of lung cancer resistance after treatment with EGFR inhibition and vaccine therapy were investigated. This case report, together with data from the longitudinal lung cancer study TRACERx, highlight the importance of understanding when targeted variants are acquired during the cancer’s evolutionary history.